biogen inc previous biogen idec inc engag develop manufactur commerci therapi
compani product address diseas multipl sclerosi non-hodgkin lymphoma nhl rheumatoid arthriti ra crohn
diseas cd psoriasi compani four product avonex interferon rituxan rituximab tysabri
natalizumab fumaderm dimethylfumar monoethylfumar salt avonex use treatment relaps form
multipl sclerosi ms rituxan one sell oncolog therapeut unit state rituxan approv nhl
tysabri approv treatment relaps form ms fumaderm act immunomudul compani also
product candid oral fumar monoclon antibodi mab galiximab mab
lumiliximab human mab ocrelizumab lixivaptan oral compound potenti treatment hyponatremia
rank
return equiti
price book
incom statement summari figur billion
long-term fundament rank
short-term technic rank
biogen idec rank number list
medical/biomed compani trade today unit
state market capit billion
medical/biomed compani highest total
asset highest revenu
within sector rel low price-to-earnings low p/e/g
low p/
strong rel roe roa final
earn growth past month
stock score set
involv valuat size
financi perform
rank accord
averag valu
rank lowest
rank
short term fall combin weak volum result
weak momentum fall day
significantli price discount
move averag price rang
trade discount
high premium
low invest exactli one year ago worth
capit loss
stock score set
price perform trade
volum rank
accord averag
valu paramet
highest rank
lowest rank
biogen idec inc place bss rank perform past year percentil rank
biogen idec inc new entrant pwc list top global compani rank mcap march
largest revenu ft global
rank newsweek corpor knight capit world greenest compani outstand score
carbon product wast product product
largest revenu forb global
new entrant industri week list world largest manufactur revenu rank
sector total bracket
revenu billion aggreg sector revenu
billion previou year
net profit billion aggreg sector net profit
billion previou year
ebit billion aggreg sector ebit
billion previou year
mcap billion aggreg sector mcap
billion previou year
price-to-earnings versu sector averag
market averag estim share trade
current year price-to-earnings forward year price-to-earnings
price/sal versu sector averag estim
share trade current year price/sal
forward year price/sal
price/earnings/growth base year-on-year
growth trail month ep versu sector
averag market averag estim
share trade current year price earn growth
forward year price earn growth
 ratio defin jame tobin mcap divid
total asset compar rest market
stock under-valued
return equiti versu sector averag
market averag
total liabilities/ebitda less compar
favour joseph piotroski benchmark
return asset versu sector averag
market averag
return capit employ versu sector averag
market averag
per du pont analysi return equiti high
comput net profit margin time
asset turnov sales/asset time leverag factor
total assets/sharehold equiti
improv last year
also follow criteria set benjamin graham
earnings-to-pric yield least twice triple-a bond
stock earn yield time triple-a
bond yield
current ratio two current asset time
stabil growth earn last year defin
two declin greater year-end
earn declin earn last
trail twelv month price-to-earnings cyclic
adjust price earn cape well cape
histor averag last year
cape develop economist robert shiller base
methodolog benjamin graham david dodd
smooth earn across period base move
averag quarter
earn yield greater benchmark yield
earn yield time bond yield
growth quarterli revenu net incom
previou correspond period pcp quarterli revenu
million million
previou correspond period pcp quarterli net profit
million million
debt equiti ratio well within safe benchmark
figur moreov improv past three year
turnov quarter
return equiti
return asset
price premium volum
weight averag price vwp given
premium one hundr fifty-two time
ninety-eight time last year
downsid upsid probabl estim
market stock unit trade
today stock rel strength
indic trail market
indic exponenti move averag ema
minu ema neg
price/map biogen idec lower
price/map
last three month stock hit new low
price map ratio bearish indic
past day ratio time
suggest downsid stock trade
map map lower
map bearish indic
map decreas decreas anoth
price book higher averag
total nasdaq market estim share trade
current year price book forward year price
book
averag annual compound return share price
last year under-perform averag
annual compound return
year-on-year earn growth versu sector averag
stock score mere set
return asset improv
qualiti earn oper cash-flow exce net
reduct total share issu
improv asset turnov growth revenu
exceed growth asset
price book valu
volum index average
stock trade low
high averag daili volatil place
stock quartil market mean least
result report
us million except per share data share outstand
revenu therapeut program
expens
sale exclud amort impair acquir
research develop
sell gener administr
loss asset liabil held sale
amort impair acquir intang asset
acquir in-process research develop
loss gain fair valu remeasur conting
total cost expens
incom oper
incom incom tax expens equiti loss
investe net tax
equiti loss investe net tax
netincom loss attribut non-controlling interest netoftax
net incom attribut biogen inc
basic earn per share attribut biogen inc
dilut earn per share attribut biogen inc
weighted-averag share use calcul
basic earn per share attribut biogen inc
dilut earn per share attribut biogen inc
cash equival
due therapeut program
asset held sale
properti plant equip net
invest asset
liabil held sale
accru expens
commit conting
accumul comprehens loss
treasuri stock cost
total liabil equiti
flow oper activ
adjust reconcil net incom net cash flow
depreci amort impair
acquir in-process research develop
loss asset liabil held sale
unreal gain loss strateg invest
chang oper asset liabil net
accru expens current liabil
incom tax asset liabil
chang oper asset liabil net
net cash flow provid oper activ
flow invest activ
proce sale matur market secur
purchas market secur
conting consider paid relat fumapharm ag
purchas properti plant equip
acquir in-process research develop
net cash flow provid invest activ
flow financ activ
purchas treasuri stock
payment relat issuanc stock share-bas
net cash flow use financ activ
net increas decreas cash cash equival
effect exchang rate chang cash cash equival
cash equival begin period
cash equival end period
quarterli report sequenti growth
quarterli report biogen idec report sequenti rise quarterli net profit
biogen idec announc net profit quarter-end march previou
quarter year-earli period
sequenti growth ep
sequenti growth revenu
sequenti growth net profit
compar previou correspond period pcp year-over-year ep revenu
net profit
pcp growth ep
pcp growth revenu
pcp growth net profit
result report annual
us million except per share data share outstand
revenu therapeut program
expens
sale exclud amort impair acquir
research develop
sell gener administr
amort impair acquir intang asset
acquir in-process research develop
loss fair valu remeasur conting
total cost expens
incom oper
incom incom tax expens equiti loss
investe net tax
equiti loss investe net tax
net incom loss attribut non-controlling interest net tax
net incom attribut biogen inc
basic earn per share attribut biogen inc
dilut earn per share attribut biogen inc
weighted-averag share use calcul
basic earn per share attribut biogen inc
dilut earn per share attribut biogen inc
cash equival
due therapeut program
properti plant equip net
invest asset
current portion note payabl
accru expens
commit conting
accumul comprehens loss
treasuri stock cost million million share
total liabil equiti
flow oper activ
adjust reconcil net incom net cash flow
depreci amort impair
acquir in-process research develop
chang oper asset liabil net
due therapeut program
accru expens current liabil
incom tax asset liabil
net cash flow provid oper activ
flow invest activ
proce sale matur market secur
purchas market secur
conting consider relat fumapharm ag acquisit
acquir in-process research develop
purchas properti plant equip
acquisit intang asset
purchas inc stock
invest samsung bioepi
net cash flow use invest activ
flow financ activ
purchas treasuri stock
payment relat issuanc stock share-bas
net distribut non-controlling interest
repay borrow
net cash contribut bioverativ inc
net cash flow use financ activ
net increas decreas cash cash equival
effect exchang rate chang cash cash equival
cash equival begin year
cash equival end year
earn cont op margin
annual report biogen idec net profit
biogen idec report net profit year-end decemb
major chang compar previou year
total revenu
ebit total asset
total non-curr asset total asset
fix asset total asset
net tangibl asset per share
ebit margin
work capit total asset
retain earn total asset
total current asset total asset
total revenu total asset steadi
debt equiti steadi
total liabil total asset steadi
current ratio steadi
intang total asset
short-term invest total asset
profit/ loss tax
year-on-year comparison per share figur
year-on-year comparison perform ratio
return equiti
return asset
total debt net tangibl asset
total liabil ebitda
debt/equ
total liabilities/tot asset
current ratio
common size ratio asset
total non-curr asset total asset
intang total asset
total current asset total asset
fix asset total asset
short-term invest total asset
common size ratio sale
profit tax sale
sale market expens sale
good sold sale
tax expens sale
five-year record growth perform
last year total revenu averag ebitda averag net profit averag compound
annual growth rate compound-annual-growth-rate averag total revenu net profit ebitda
profit tax
oper cash flow
sale
past year incom tax profit tax decreas
base issu equiti share market
capitalis billion largest
medical/biomed compani total revenu
may biogen idec biogen present data
annual meet affirm long-term safeti durabl
treatment spinraza nusinersen
today announc new data affirm safeti durabl
spinraza nusinersen highlight clinic meaning
benefit individu spinal muscular atrophi sma data
shine extens studi patient follow
four year nurtur studi pre-symptomat infant
evalu phosphoryl neurofila heavi chain pnf-
 biomark featur present
annual meet american academi neurolog
mileston studi mark new chapter
mean live sma insight provid invalu
understand long-term experi rare diseas
chief medic offic
detail click
today announc present new data across industry-
lead neurosci portfolio advanc clinic
develop program annual meet
american academi neurolog philadelphia pa may
total present key data focu
spinal muscular atrophi sma multipl sclerosi ms
detail click
april biogen announc three new nomine
elect board director
nomine bring decad manag global oper
experi includ lead healthcar compani
today announc nomin john chiminski william
hawkin jesu manta stand elect
compani board director annual meet
stockhold schedul june
detail click
april biogen idec result oper
result oper financi condit first quarter
end march copi press releas furnish
exhibit incorpor herein refer
detail click
recommend fund unit
kingdom treatment infant children adult
spinal muscular atrophi
today announc nation institut
excel unit kingdom recommend
fund spinraza nusinersen
servic nh posit recommend treatment
infant children adult spinal muscular atrophi
sma includ pre-symptomat symptomat sma type
detail click
may biogen idec data demonstr biogen
leadership commit innov ms
present new data illustr on-going commit
improv care peopl live multipl sclerosi ms
annual meet american academi neurolog
philadelphia may data support well-
tecfidera dimethyl fumar tysabri natalizumab
detail click
march biogen idec biogen eisai discontinu
phase engag emerg trial aducanumab
unlik meet primari endpoint lead decis
discontinu trial
eisai co ltd tokyo japan today announc decis
discontinu global phase trial engag emerg
design evalu efficaci safeti aducanumab
patient mild cognit impair due alzheim
diseas mild alzheim diseas dementia
detail click
novemb biogen idec appoint robin kramer
biogen idec appoint robin kramer vice presid
appoint take effect
may biogen present new interim data phase
clinic studi tofersen potenti
treatment subtyp famili amyotroph later
announc today interim result phase studi tofersen
antisens oligonucleotid aso studi potenti
treatment amyotroph later sclerosi al adult
detail click
april data publish neurolog show treatment
spinraza nusinersen improv motor function
provid long-term benefit individu later-onset
today announc data open-label studi
safeti toler spinraza individu
later-onset spinal muscular atrophi sma publish
peer-review journal neurolog medic journal
american academi neurolog
detail click
april biogen idec data publish neurolog show
treatment spinraza nusinersen improv motor
function provid long-term benefit individu
later-onset spinal muscular atrophi
today announc data open-label studi
safeti toler spinraza individu
later-onset spinal muscular atrophi sma publish
peer-review journal neurolog medic journal
american academi neurolog
detail click
april biogen inc compani issu press
releas announc nomin john chiminski
jesu manta stand elect
compani board director annual meet
stockhold schedul june
detail click
april biogen idec biogen continu advanc
innov sma new data adult infant
present mda clinic scientif confer
today announc present new data illustr rapidli
progress natur spinal muscular atrophi sma adult
adolesc older children muscular dystrophi
associ mda clinic scientif confer orlando
detail click
march board director biogen inc
compani author program repurchas billion
compani common stock share repurchas
program share repurchas program
expir date share repurchas share
repurchas program retir
detail click
report buy sell trail month continu
share
share
report institut buy sell share
hold end quarter
report hold institut decemb
total report hold institut share
report hold institut
issu capit
net buying/ sell institut trail month ttm
usd valu
montreal
new york mellon corp
state new jersey common
state tennesse treasuri
board manag creation sharehold valu
board director year sinc appoint
mr vounatso serv chief execut offic
one director sinc januari prior april
appoint chief execut offic
serv execut vice presid chief commerci
offic prior join mr vounatso spent year
merck co inc pharmaceut compani
recent serv presid primari custom busi
merck custom centric role led merck
global primari care busi unit role encompass
biosimilar group develop institut strateg
framework enhanc compani relationship key
constitu includ signific provid payer
retail world largest govern mr vounatso
previous held leadership posit across europ china
merck prior mr vounatso held manag
posit ciba-geigi mr vounatso receiv
certif medicin universit victor segalen
bordeaux ii franc hec school
manag pari
mr vounatso signific knowledg experi
respect biotechnolog healthcar pharmaceut
servic execut pharmaceut industri
studi medicin part educ background
former public compani directorship held past
dr papadopoulo serv one director sinc
independ chairman sinc june dr
papadopoulo also serv chairman inc
drug discoveri develop compani co-found
inc biopharmaceut
compani previous invest banker cowen
 co llc financi servic compani focus
biotechnolog pharmaceut sector
retir vice chairman august prior join
cowen co dr papadopoulo serv year
invest banker painewebb inc financi servic
compani recent chairman painewebb
develop corp painewebb subsidiari focus
biotechnolog dr papadopoulo also director bg
medicin inc diagnost compani focus
develop commerci cardiovascular diagnost
work invest banker focus life scienc
industri dr papadopoulo bring board director
firsthand understand demand establish grow
run life scienc busi
scienc technolog
mr pangia serv director compani
period compani oper idec
pharmaceut serv director sinc
follow idec merger inc mr pangia
partner ivi capit partner llc gener partner ivi
healthcar capit privat equiti fund special
healthcar invest sinc
also chief execut offic ivi sport medicin llc
medic devic compani octob octob
also serv chief execut offic highland
mr pangia self-employ invest
banker held variou senior manag
posit painewebb financi servic compani
includ execut vice presid director invest
bank painewebb incorpor new york member
board director painewebb inc chairman
painewebb properti inc member sever
painewebb execut oper committe
mr pangia signific financi acumen breadth
expertis within healthcar industri
compens manag develop chair
former public compani directorship held past
former public compani directorship held past
jeffrey capello execut vice presid chief
offic mr capello join us decemb execut
vice presid chief offic bring year
experi financ recent execut vice
presid chief offic beacon health option
inc previou experi includ found run
compani monomi advisor serv chief
offic ortho clinic diagnost
corpor earlier career
partner boston amsterdam offic pwc believ
mr capello strong public compani financi experi
allow play critic role aim execut
build pipelin
dr sherwin serv one director sinc
dr sherwin current divid time advisori work
life scienc industri patient care teach
specialti medic oncolog clinic professor
medicin univers california san francisco
volunt attend physician hematology-oncolog
current serv ventur partner third ventur
llc dr sherwin previous serv chairman
ceregen inc life scienc compani co-found
acquisit sangamo bioscienc inc
also co-found chairman abgenix inc
antibodi compani acquir amgen inc
octob serv chief execut
offic cell genesi inc life scienc compani
chairman compani merger biosant
pharmaceut inc inc octob
prior held variou posit genentech inc
life scienc compani recent vice presid clinic
research dr sherwin member board director
inc inc
clinical-stag life scienc compani
dr sherwin extens knowledg life scienc industri
bring year experi senior leadership
posit larg small publicli trade life scienc
compani board director
scienc technolog
former public compani directorship held past
ms dorsa serv one director sinc
ms dorsa serv execut vice presid chief
financi offic public servic enterpris group incorpor
diversifi energi compani april retir
octob serv board director
februari april februari april
serv senior vice presid global human health
strategi integr merck co inc pharmaceut
compani novemb januari ms dorsa
serv senior vice presid chief offic
novemb serv senior vice presid
chief offic avaya inc telecommun
compani januari ms dorsa held variou
financi oper posit merck co inc includ
vice presid treasur execut director
custom market execut director price
strateg plan ms dorsa also serv director
inc inc
biotechnolog compani truste goldman
sach etf trust goldman sach
renaiss fund goldman sach incom
opportun fund invest fund within goldman sach
ms dorsa signific financi account expertis
deep knowledg pharmaceut industri strateg
perspect industri particularli valuabl board
director overse growth initi review
intern develop project extern opportun
former public compani directorship held past
mr posner serv one director sinc
mr posner privat investor sinc march
presid point rider group llc consult
advisori servic firm serv predominantli financi
servic industri well institut investor seek
make control invest industri march
mr posner serv presid chief execut
offic co-chief invest offic clearbridg advisor
llc asset manag compani wholly-own
subsidiari prior mr posner co-found
hygrov partner llc privat invest fund
serv manag five year serv
portfolio manag analyst fidel invest
financi servic compani
warburg pincu asset management/credit suiss asset
manag also serv co-chief invest
offic director research mr posner also serv
director aqr fund ltd specialti
insur reinsur provid
given substanti experi lead institut
invest manag advisor mr posner bring
profession investor perspect signific manag
financi expertis valuabl board director
overse strategi enhanc stockhold valu
former public compani directorship held past
ms schenk serv director compani
period compani oper idec
pharmaceut serv director sinc
follow idec merger inc ms schenk
attorney consult privat practic extens public
polici busi experi also member
board overs scripp research institut director
california high speed rail author board truste
univers california san diego foundat
serv chief staff governor california
time led effort creat institut
scienc innov univers california
head state execut branch risk manag team post
california energi crisi
ms schenk member unit state hous
repres repres san diego california serv
hous energi commerc committe special
emphasi biotechnolog
california secretari busi transport hous
time form california commiss
industri innov ms schenk member board
director energi servic
develop compani serv compens
committe execut committe chair
environment health safeti technolog committe ms
schenk also nation associ corpor director
nacd board leadership fellow member nacd
advisori council risk oversight fellow ucla
luskin school public affair ms schenk select
nacd directorship honore
ms schenk strong public polici govern legal privat
sector experi provid vital insight board director
signific issu affect highli regul life
scienc industri bring public sector oper
manag expertis board director
demonstr commit boardroom excel
complet nacd comprehens program studi
corpor director supplement skill set
on-going engag director commun access
compens manag develop
former public compani directorship held past
experi dr denner serv one director
sinc dr denner found partner chief
invest offic sarissa capit manag lp
regist invest advisor found sarissa
capit focus improv strategi compani
enhanc stockhold valu dr denner
serv senior manag director icahn capit prior
serv portfolio manag vike global investor
privat invest fund invest
manag global asset manag firm dr denner
also director medicin compani biopharmaceut
qualif dr denner signific experi overse
oper research develop healthcar
compani evalu corpor govern matter
also extens experi investor particularli
respect healthcar compani possess broad
former public compani directorship held past
dr rowinski serv one director sinc
serv presid rgenix inc privately-held life
scienc compani sinc novemb execut
also chief scientif offic clearpath
develop co rapidli advanc develop stage
therapeut asset pre-defin human proof-of-concept
mileston januari novemb dr rowinski
head research develop chief medic
offic inc biotechnolog compani
focus discoveri develop therapeut
target cancer stem cell dr rowinski adjunct professor
medicin new york univers independ
consult sinc januari prior chief
medic offic primros therapeut inc start-up
biotechnolog compani focus develop
therapeut polycyst kidney diseas august
acquisit septemb decemb
serv chief medic offic execut vice
presid imclon system incorpor life scienc
compani dr rowinski held sever
posit cancer therapi research center institut
drug develop includ director institut director
clinic research time held sbc endow
chair earli drug develop clinic professor
medicin univers texa scienc center san
antonio dr rowinski associ
professor oncolog john hopkin school medicin
staff john hopkin hospit dr rowinski
serv director fortress biotech inc biopharmaceut
compani verastem inc biopharmaceut compani
dr rowinski extens research drug develop
experi broad scientif medic knowledg
biogen committe membership compens
scienc technolog
former public compani directorship held past
ms leam serv one director sinc
ms leam independ consult sinc
serv chief execut offic
presid tuft health provid healthcar
insur ms leam serv sever
execut posit tuft health includ presid
chief oper offic chief offic
ms leam well-develop leadership skill financi
acumen provid insight healthcar reimburs
payer market serv year senior
oper financi manageri role
former public compani directorship held past
dr mulligan serv one director sinc
dr mulligan current professor genet
emeritu harvard medic school serv
professor genet director harvard
gene therapi initi also current
serv portfolio manag icahn capit lp posit held
sinc march prior harvard dr mulligan professor
molecular biolog massachusett institut
technolog member whitehead institut biomed
research chief scientif offic somatix therapi
corpor drug discoveri develop compani
found dr mulligan found partner sarissa capit
manag lp regist invest advisor
dr mulligan name macarthur foundat fellow
dr mulligan scientif expertis area molecular
biolog genet gene therapi biotechnolog well
extens experi within healthcar industri includ
overse oper research develop
scienc technolog chair
compens manag develop
former public compani directorship held past
susan alexand execut vice presid chief legal
corpor servic secretari serv
execut committe sinc prior
decemb ms alexand serv execut vice
presid gener counsel corpor secretari
januari ms alexand serv senior vice
presid gener counsel corpor secretari
servic compani ms alexand serv
gener counsel softwar compani
ms alexand serv counsel
corpor specialti chemic perform materi
compani prior ms alexand partner law
firm hinckley allen snyder fine ambrogn ms
alexand receiv wellesley colleg
boston univers school law
mr guindo bring year experi global
pharmaceut industri held sever leadership
posit merck known msd outsid canada usa
canada usa franc africa netherland
work sever disciplin includ financ sale
market gener manag global strategi product
develop specialti acut hospit care recent
mr guindo presid manag director merck canada
report report prepar minkabu infonoid inc minkabu analyst opinion project report
suppli global market intellig llc compani profil company-rel inform co-own
minkabu infonoid inc pk clean ltd buysellsign group compani stock index price suppli
stock exchang tradeg exchang euronext deutsch brse ag bme stuttgart stock exchang tradeg exchang
exchang clear limit taiwan stock exchang tokyo stock exchang nagoya stock exchang toronto stock exchang
express opinion analyst sole person opinion author contributor report minkabu
respons accuraci complet reliabl timeli inform opinion respons error
omiss therein assum liabil direct indirect loss damag particular lost profit may
incur result relianc inform use report inform report may contain project
opinion assumpt estim forecast relat futur busi perform event intend exampl
repres predict minkabu current futur perform compani secur
minkabu make warranti regard accuraci reliabl project opinion assumpt estim forecast
liabil damag kind aris relianc inform forward-look statement guarante
futur perform involv risk uncertainti actual result may differ forward-look statement result
variou factor minkabu oblig updat correct inform report constitut recommend
make invest purchas sell specif invest product report intend give financi
invest advic conduct care independ analysi seek advic profession advisor
suitabl invest need minkabu express opinion compani secur invest
product fluctuat futur perform thereof stock price rate comment includ target price buy
sell hold creat aggreg opinion individu investor opinion analyst secur
compani rate overvalu under-valued fairlyvalu fair stock price other display ancillari
rate object fact base statist record minkabu express opinion compani secur
invest product fluctuat futur perform thereof therebi either
minkabu repres warrant report appropri avail view download locat
exclus respons complianc applic local law regul view download report report
intend use inform refer purpos constitut solicit offer make
invest purchas sell specif invest product
minkabu regist broker dealer invest advisor analyst invest banker underwrit minkabu may hold
secur refer report includ deriv instrument may busi relat compani discuss
herein without prior written consent minkabu reproduct copi transmiss transfer distribut public
similar action content report shall made
